Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Expert Opin Drug Metab Toxicol ; 9(3): 307-17, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23289968

RESUMO

INTRODUCTION: Antithrombotics are one of the most commonly prescribed classes of medication around the world. The thienopyridines are an integral part of antithrombotic therapy and are prescribed for various indications including acute coronary syndrome, peripheral vascular disease and cerebrovascular disease. These drugs have distinct metabolic pathways, which lead to the formation of active metabolites that produce both observed clinical differences as well as pharmacokinetic and pharmacodynamic differences in response. AREAS COVERED: The authors describe the pharmacokinetic and pharmacodynamic behavior of three of the currently available thienopyridines, namely ticlopidine, clopidogrel and prasugrel. The authors also describe and discuss the drug interaction and pharmacogenomic factors which may impact safety and drug efficacy. EXPERT OPINION: P2Y(12)-ADP receptor antagonism has proven to be effective at preventing thrombosis. Differences in the activation of these drugs, cytochrome metabolism, concomitant drug use and pharmacogenomics have an impact on thienopyridine use. Clopidogrel remains the thienopyridine drug with the most approved indications for use. Prasugrel has proven to be efficacious but is associated with a higher bleeding risk in comparison to clopidogrel and therefore has to be used in appropriate clinical indications.


Assuntos
Fibrinolíticos/farmacocinética , Piperazinas/farmacocinética , Piridinas/farmacocinética , Tiofenos/farmacocinética , Ticlopidina/análogos & derivados , Síndrome Coronariana Aguda/tratamento farmacológico , Hidrocarboneto de Aril Hidroxilases/genética , Hidrocarboneto de Aril Hidroxilases/metabolismo , Clopidogrel , Citocromo P-450 CYP2C19 , Interações Medicamentosas , Hemorragia/tratamento farmacológico , Humanos , Inativação Metabólica , Farmacogenética , Inibidores da Agregação Plaquetária/farmacocinética , Cloridrato de Prasugrel , Antagonistas do Receptor Purinérgico P2Y/farmacocinética , Ticlopidina/farmacocinética
2.
Semin Thromb Hemost ; 38(8): 884-92, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22930343

RESUMO

The topic of adverse effects of drugs is now receiving due attention in both the lay and medical communities. For drugs of the coagulation disorder class, such as anticoagulants and antiplatelet agents, the obvious adverse effects are bleeding from a dose too high and thrombosis from a dose too low. However, these drugs have other potential adverse effects that are not directly related to blood coagulation, yet cannot be dismissed due to their medical importance. There has been a recent advancement of several new drugs in this category and this number will soon grow as more drugs are reaching the end of their clinical trials. This article will discuss the nonhemostatic adverse effects of anticoagulants and antiplatelet drugs. As the adverse effects of bleeding and thrombosis will be excluded, this article will be in contrast to the typical discussions on the anticoagulant and antiplatelet drug classes.


Assuntos
Anticoagulantes/efeitos adversos , Inibidores da Agregação Plaquetária/efeitos adversos , Humanos
3.
Clin Appl Thromb Hemost ; 18(5): 534-7, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22311631

RESUMO

Patients with end-stage renal disease (ESRD) are known to have an elevation of a variety of abnormal thrombotic and inflammatory markers associated with high cardiovascular mortality. Vascular endothelial growth factor (VEGF) is also dysregulated in ESRD but not much is known about the serum levels of VEGF in patients with ESRD. Published reports suggest that elevated levels of VEGF may be protective to the kidney during periods of acute injury and may maintain local glomerular function. Impaired production of VEGF may lead to proteinuria, hypertension, and thrombotic microangiopathy. However, its role in chronic kidney disease or ESRD remains undefined. In our study, we analyzed blood samples of 52 patients with ESRD on stable hemodialysis regimen and measured predialysis serum levels of VEGF and compared these with blood samples obtained from 50 healthy volunteers in order to study differences between baseline levels of VEGF and also attempted to determine its role in ESRD-related cardiovascular mortality.


Assuntos
Hipertensão/sangue , Hipertensão/mortalidade , Falência Renal Crônica/sangue , Falência Renal Crônica/mortalidade , Trombose/sangue , Trombose/mortalidade , Fator A de Crescimento do Endotélio Vascular/sangue , Adulto , Idoso , Biomarcadores/sangue , Feminino , Humanos , Hipertensão/etiologia , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Proteinúria/sangue , Proteinúria/etiologia , Proteinúria/mortalidade , Diálise Renal , Trombose/etiologia
4.
J Burn Care Res ; 33(4): 453-61, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22269826

RESUMO

Oral anticoagulation used to be synonymous with warfarin until the recent approval of oral direct thrombin inhibitors and factor Xa inhibitors in United States and other countries across the world. Thrombosis prevention and treatment continue to be the main objective and goal for surgical and medical patients. Regulatory agencies continue to revise their guidelines to treat these patients with appropriate medication and for optimal duration. As the choices for oral anticoagulants increase, with many oral anticoagulant drugs currently in the pipeline awaiting completion of clinical trials, the guidelines for venous thromboembolism prevention, stroke prevention in atrial fibrillation, and treatment of acute arterial and venous thrombi will also shift from the current standards to new standards set by these clinical trials for optimal dosing and duration of treatment. However, it must be reinforced that these new oral anticoagulants are distinct pharmacological compounds with specific targets and will also have distinct clinical indications for use.


Assuntos
Antitrombinas/uso terapêutico , Inibidores do Fator Xa , Trombose/tratamento farmacológico , Trombose/prevenção & controle , Administração Oral , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Antitrombinas/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Fator Xa/uso terapêutico , Feminino , Hemostasia/efeitos dos fármacos , Humanos , Masculino , Prognóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , Tromboembolia/tratamento farmacológico , Tromboembolia/prevenção & controle , Resultado do Tratamento , Varfarina/uso terapêutico
5.
Clin Appl Thromb Hemost ; 18(3): 324-6, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22084414

RESUMO

Chronic immune thrombocytopenia (ITP) carries a poor prognosis in the elderly patients. Increasing evidence proposes that a subgroup of patients with chronic ITP may be more susceptible to ischemic stroke. An 84-year-old Caucasian man with multiple ischemic stroke risk factors presented with acute onset of slurred speech, confusion, and unsteady gait. Physical examination and neurologic imaging were consistent with a new left thalamic infarct. Platelet counts ranged between 40 000 × 10(9)/L and 65 000 × 10(9) /L. Antiplatelet therapy for his newly acquired stroke was not initiated considering his low platelet counts and for mildly symptomatic thrombocytopenia, and the patient was discharged home. Both hematologic and neurologic guidelines for the management of chronic ITP and stroke have contradictory goals. Although anticoagulation is mandated in acute stroke, ITP causes low platelet counts that increase bleeding complications.


Assuntos
Infarto Cerebral/sangue , Infarto Cerebral/etiologia , Púrpura Trombocitopênica Idiopática/sangue , Púrpura Trombocitopênica Idiopática/complicações , Acidente Vascular Cerebral/sangue , Acidente Vascular Cerebral/etiologia , Idoso de 80 Anos ou mais , Infarto Cerebral/terapia , Humanos , Masculino , Contagem de Plaquetas , Púrpura Trombocitopênica Idiopática/terapia , Acidente Vascular Cerebral/terapia
6.
Annu Rev Pharmacol Toxicol ; 52: 79-99, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-21819239

RESUMO

Since the discovery of heparin nearly a century ago, there have been large gaps in the development of anticoagulants. The discovery of warfarin was the first step toward using oral anticoagulants, but warfarin use has been associated with its own challenges from the perspectives of the prescribing physician and the patient. Warfarin, along with other coumarins, has a narrow therapeutic index, requires frequent monitoring, exhibits interindividual response variations, and is associated with several adverse effects. Frequent drug and food interactions contribute to potential safety and efficacy compromise. The indications for use of oral anticoagulants have increased, as these drugs are used not only for thrombosis management but also for cardiovascular indications, producing more challenges for oral anticoagulant use. Factor Xa and thrombin targeting has provided a rational approach to develop new oral anticoagulants with improvements over warfarin. In this review, the pharmacology of warfarin and the pharmacology of the newly developed oral anti-Xa and antithrombin agents are discussed.


Assuntos
Anticoagulantes/farmacologia , Antitrombinas/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Varfarina/uso terapêutico , Administração Oral , Antitrombinas/efeitos adversos , Inibidores do Fator Xa , Interações Alimento-Droga , Hemostáticos/metabolismo , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Farmacogenética , Protrombina/antagonistas & inibidores , Trombina/uso terapêutico , Trombose/tratamento farmacológico , Vitamina K/antagonistas & inibidores , Varfarina/efeitos adversos
7.
Clin Appl Thromb Hemost ; 17(6): 633-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21949036

RESUMO

INTRODUCTION: Several generic low-molecular-weight heparins (LMWHs) have recently become available worldwide, including the United States. Companies have filed for regulatory approval of generic versions in many countries, based only on compound biochemical characteristics or its immunogenicity. METHODS: Prospective study to evaluate the comparative effect of 2 enoxaparins (Sanofi-Aventis branded enoxaparin [SAe] vs eurofarma-enoxaparin [Ee], a generic version) as prophylaxis for venous thromboembolism (VTE) following major abdominal surgery. A total of 200 patients were randomized in a 1:1 ratio either to receive 40 mg of SAe or Ee subcutaneously (sc) once daily (od) postoperatively for 7 to 10 days. Compressive ultrasound was performed on day 10 + 4. RESULTS: No statistically significant differences between the 2 groups were detected. In all, 2 SAe patients presented deep vein thrombosis ([DVT] 2.1%), none of the Ee group. No major bleeding events occurred. CONCLUSIONS: This exploratory trial suggests that the generic LMWH is probably as safe and as effective as the branded enoxaparin (Lovenox, Brazil) in the prophylaxis of VTE in this population.


Assuntos
Abdome/cirurgia , Anticoagulantes/uso terapêutico , Medicamentos Genéricos/uso terapêutico , Enoxaparina/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Tromboembolia Venosa/prevenção & controle , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Tromboembolia Venosa/tratamento farmacológico
8.
Clin Appl Thromb Hemost ; 17(6): E218-23, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21873362

RESUMO

Systemic vascular changes contribute to both the pathogenesis and thrombotic comorbidities of end-stage renal disease (ESRD). This study aims to profile various biomarkers and better understand their role in the pathogenesis of ESRD. Plasma samples from 49 patients with ESRD and 56 control individuals were analyzed for markers for inflammation, specifically C-reactive protein (CRP), tumor necrosis factor receptor 1 (TNFR1), neutrophil gelatinase-associated lipocalin (NGAL); thrombomodulin (TM); neuron-specific enolase (NSE), and thrombosis-D-dimer (DD). Compared to controls, all markers studied showed a statistically significant upregulation in patients with ESRD. These results indicate a polypathologic process in patients with ESRD, leading to cardiovascular and cerebrovascular events. However, the clinical significance of previously untested markers, such as TNFR1, NGAL, and NSE, still needs to be further explored. This study further validates the role of endothelial damage and endogenous thrombotic processes in ESRD as evidenced by the increased levels of TM and DD.


Assuntos
Mediadores da Inflamação/sangue , Falência Renal Crônica/sangue , Análise Serial de Proteínas/métodos , Proteínas de Fase Aguda , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Humanos , Lipocalina-2 , Lipocalinas/sangue , Fosfopiruvato Hidratase/sangue , Proteínas Proto-Oncogênicas/sangue , Receptores Tipo I de Fatores de Necrose Tumoral/sangue , Fatores de Risco , Trombomodulina/metabolismo , Regulação para Cima
9.
Expert Rev Cardiovasc Ther ; 9(4): 525-34, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21517735

RESUMO

Coronary artery diseases leading to heart attacks and cerebral artery disease leading to stroke rank number one and two respectively, in causing acute vascular events. Thrombosis of the veins and pulmonary embolism are major causes of hospital-associated acute vascular events. Increased bodyweight at all stages of life, from the very beginning of life (intrauterine growth), to adulthood, promote risks that are associated with vascular disease. An increase in bodyweight promotes risk factors for developing acute vascular events by a variety of mechanisms. In this article, we briefly describe some of the major risks associated with vascular diseases leading to vascular injury, and the modulatory role that increased bodyweight plays in promoting these risks.


Assuntos
Obesidade/complicações , Doenças Vasculares/etiologia , Aumento de Peso , Humanos , Fatores de Risco
11.
Clin Appl Thromb Hemost ; 17(6): E202-4, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21422058

RESUMO

Disseminated intravascular coagulation (DIC) results in the catastrophic simultaneous activation of thrombotic and hemorrhagic processes. Its pathophysiology and the role of inflammation and microparticles (MPs) are not fully understood. Microparticles represent small phospholipid-expressing procoagulant vesicular fragments, released with cellular disruption and apoptosis. Functional MPs were measured in 100 random patients from a population of patients with DIC. Plasma samples from 30 normal male and female volunteers were used as control. Commercial Annexin trapping method was used to determine procoagulant activity of MPs. Mean ± SD concentration of MPs in the DIC group was 24.6 ± 14.2 nmol/L (range: 0.0-60.0 nmol/L), significantly higher than the control group: 8.5 ± 4.3 nmol/L (range: 1.3-17.4 nmol/L). Distribution curves and scattergrams showed that MPs concentration in the DIC samples was more widespread. This demonstrates that MPs are upregulated in patients with DIC and may mediate the hemostatic activation and inflammatory responses in this syndrome.


Assuntos
Micropartículas Derivadas de Células/metabolismo , Micropartículas Derivadas de Células/patologia , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/patologia , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Adulto , Feminino , Humanos , Inflamação/sangue , Inflamação/patologia , Masculino , Contagem de Plaquetas , Regulação para Cima
12.
Thromb J ; 9(1): 5, 2011 Mar 28.
Artigo em Inglês | MEDLINE | ID: mdl-21443789

RESUMO

BACKGROUND: The prevention of venous thromboembolism has been identified as a leading priority in hospital safety. Recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionated heparin, low-molecular-weight heparins and fondaparinux. Prescribing decisions in venous thromboembolism management may seem complex due to the large range of clinical indications and patient types, and the range of anticoagulants available. METHODS: MEDLINE and EMBASE databases were searched to identify relevant original articles. RESULTS: Low-molecular-weight heparins have nearly replaced unfractionated heparin as the gold standard antithrombotic agent. Low-molecular-weight heparins currently available in the US are enoxaparin, dalteparin, and tinzaparin. Each low-molecular-weight heparin is a distinct pharmacological entity with different licensed indications and available clinical evidence. Enoxaparin is the only low-molecular-weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment. Enoxaparin also has the largest body of clinical evidence supporting its use across the spectrum of venous thromboembolism management and has been used as the reference standard comparator anticoagulant in trials of new anticoagulants. As well as novel oral anticoagulant agents, biosimilar and/or generic low-molecular-weight heparins are now commercially available. Despite similar anticoagulant properties, studies report differences between the branded and biosimilar and/or generic agents and further clinical studies are required to support the use of biosimilar low-molecular-weight heparins. The newer parenteral anticoagulant, fondaparinux, is now also licensed for venous thromboembolism prophylaxis in surgical patients and the treatment of acute deep-vein thrombosis; clinical experience with this anticoagulant is expanding. CONCLUSIONS: Parenteral anticoagulants should be prescribed in accordance with recommended dose regimens for each clinical indication, based on the available clinical evidence for each agent to assure optimal safety and efficacy.

13.
Clin Appl Thromb Hemost ; 17(2): 126-35, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21288929

RESUMO

BACKGROUND: The contaminant isolated from contaminated heparin was oversulfated chondroitin sulfate (OSCS). Other possible contaminants should be evaluated. METHODS: Contaminants were isolated from recalled contaminated heparin and were compared to OSCS from animal sources and to heparin by-products synthetically persulfated. RESULTS: A great variability in molecular weight was observed in the isolated contaminants. Dermatan sulfate with high-molecular-weight in addition to OSCS was detected. Oversulfated chondroitin sulfate from different sources as well as heparin by-products produced activation of prekallikrein to kallikrein at variable rates as measured by the generation of kallikrein. All agents produced activation of the complement system. All compounds formed complexes with platelet factor 4 (PF4) and all produced (14)C serotonin release in the heparin-induced thrombocytopenia (HIT) analysis. The agents also exhibited variable anticoagulant responses that were mostly mediated via heparin cofactor II. CONCLUSION: These results suggest that heparin contaminants represent a heterogeneous group of oversulfated glycosaminoglycans (OSGAGs) which may mediate multiple pathophysiologic responses.


Assuntos
Anticoagulantes/análise , Sulfatos de Condroitina/efeitos adversos , Sulfatos de Condroitina/análise , Dermatan Sulfato/efeitos adversos , Dermatan Sulfato/análise , Contaminação de Medicamentos , Trombocitopenia/induzido quimicamente , Animais , Anticoagulantes/uso terapêutico , Sulfatos de Condroitina/farmacologia , Ativação do Complemento/efeitos dos fármacos , Dermatan Sulfato/farmacologia , Ativação Enzimática/efeitos dos fármacos , Heparina , Humanos , Fator Plaquetário 4/metabolismo , Pré-Calicreína/metabolismo , Serotonina/metabolismo , Trombocitopenia/metabolismo
14.
Clin Appl Thromb Hemost ; 17(1): 66-9, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21220365

RESUMO

INTRODUCTION: Compositional variations among biosimilar enoxaparin could lead to a differential immunogenic response between these preparations. METHODS: Enoxaparin (Clexane, n = 110) and a biosimilar version (Cutenox, n = 110) were administered to healthy volunteers in Brazil, 40 mg subcutaneous (SQ), daily, for 10 days. Blood was collected at baseline, days 1 and 10, and analyzed for antiheparin/PF4 antibody (AHPF4 antibodies) titers and subtypes by enzyme-linked-immunosorbent serologic assay (ELISA). RESULTS: Low-molecular-weight heparin (LMWH) treatment resulted in AHPF4 antibodies generation, with differences on day 10 (P < .05). Antibody subtyping (immunoglobulin [Ig] G, IgA, IgM) demonstrated different profiles between LMWH with statistical significance for IgG (Clexane 10 = 0.21 ± 0.06, Cutenox 10 = 0.28 ± 0.10, P < .0001) and IgA (Clexane 10 = 0.15 ± 0.02, versus Cutenox 10 = 0.13 ± 0.02, P < .0001) on day 10, with a significant drug effect (P < .0001) and significant time by drug interaction (P = .0009). All antibody titers were stated in terms of optical density (OD) units. CONCLUSION: LMWHs immunogenic potential varies to generate AHPF4 antibodies and subtypes and cross-reactivity with preformed antibodies. Such parameters may be useful in defining the biosimilar LMWHs bioequivalence. Future studies evaluating the immunogenicity of biosimilar drugs are warranted.


Assuntos
Anticorpos/imunologia , Anticoagulantes/administração & dosagem , Anticoagulantes/imunologia , Medicamentos Genéricos/administração & dosagem , Enoxaparina/administração & dosagem , Enoxaparina/imunologia , Anticorpos/sangue , Anticoagulantes/efeitos adversos , Medicamentos Genéricos/efeitos adversos , Enoxaparina/efeitos adversos , Feminino , Humanos , Injeções Subcutâneas , Masculino , Estudos Prospectivos
15.
Clin Appl Thromb Hemost ; 17(6): 567-71, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22345625

RESUMO

Thromboembolic disease is a common complication of hip fracture in the elderly. Anticoagulants represent a standard of care in preventing postoperative thrombotic complications following surgical fixation. We asked whether levels of antibody to heparin-platelet factor 4 (PF4) complex were differentially present in unfractionated heparin (UFH) versus Enoxaparin, following hip fracture and whether one particular subtype of antibodies was more prevalent. Plasma samples from elderly patients sustaining a hip fracture treated with either enoxaparin or UFH were collected pre- and postoperatively and analyzed using enzyme-linked immunosorbent assay (ELISA) sandwich method for the prevalence of antiheparin-PF4 antibodies and later subtyped. The prevalence of antiheparin-PF4 antibodies was higher in the UFH group especially on postoperative day 7. Patients treated with UFH showed a greater prevalence of antiheparin-PF4 antibodies and a greater prevalence of immunoglobulin G (IgG) subtype. Heparin and enoxaparin are capable of generating heparin-induced thrombocytopenia (HIT) antibodies in elderly patients undergoing orthopedic surgery but perhaps not to the same extent. When comparing low-molecular-weight heparin (LMWH) with UFH, the incidence of new antiheparin-PF4 antibody production is higher in patients treated with UFH.


Assuntos
Anticorpos/imunologia , Enoxaparina/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Heparina/imunologia , Fraturas do Quadril/tratamento farmacológico , Fator Plaquetário 4/imunologia , Idoso , Anticoagulantes/efeitos adversos , Anticoagulantes/uso terapêutico , Enoxaparina/efeitos adversos , Feminino , Heparina/efeitos adversos , Heparina/uso terapêutico , Heparina de Baixo Peso Molecular/efeitos adversos , Fraturas do Quadril/imunologia , Fraturas do Quadril/cirurgia , Humanos , Masculino , Estudos Prospectivos , Ensaios Clínicos Controlados Aleatórios como Assunto , Trombose/tratamento farmacológico , Trombose/etiologia , Trombose/prevenção & controle , Trombose Venosa/tratamento farmacológico , Trombose Venosa/etiologia , Trombose Venosa/prevenção & controle
16.
Clin Appl Thromb Hemost ; 17(2): 197-201, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21159704

RESUMO

This study was performed to develop a simple scoring system to aid in the early clinical management of patients suspected of heparin-induced thrombocytopenia (HIT) with regard to decisions for continued heparin therapy. The system was designed to arrive at low (0) or possible (1) probability scores without knowledge of laboratory test results (except platelet counts) to avoid delays. As the safest clinical approach is to discontinue heparin, intermediate and high scores were combined. Critically ill VA hospital patients (n = 100) with a ≥30% fall in platelet count were assessed by platelet aggregation (PA), (14)C-serotonin release assay ((14)C-SRA), and GTI ELISA. In this population, 53% were scored 1 and of these 43% were positive by laboratory test. Emphasizing the decision to discontinue heparin, the clinical signs of HIT were paramount for the immediate determination of a diagnosis of HIT without dependence on a positive laboratory test.


Assuntos
Anticoagulantes/efeitos adversos , Heparina/efeitos adversos , Monitorização Fisiológica/métodos , Trombocitopenia , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/administração & dosagem , Ensaio de Imunoadsorção Enzimática , Feminino , Heparina/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária , Contagem de Plaquetas , Serotonina/sangue , Trombocitopenia/sangue , Trombocitopenia/induzido quimicamente , Trombocitopenia/diagnóstico , Fatores de Tempo
17.
Clin Appl Thromb Hemost ; 17(3): 302-4, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21159713

RESUMO

Patients with end-stage renal disease (ESRD) undergoing regular hemodialysis have high annual mortality rate of around 15%. The most predominant cause of death is cardiovascular, which is not entirely explainable with conventional cardiac risk factors present in these patients. It has been postulated that ESRD is a chronic inflammatory and hypercoagulable condition with marked elevation of several markers that may explain this high mortality. In the current study, patients with ESRD on a stable regimen of hemodialysis were studied for the inflammatory and thrombogenesis markers to explain this phenomenon. The parameters studied were of thrombogenesis-thrombin-antithrombin III complex (TAT), prothrombin fragment (F1.2), D-dimer, and fibrinopeptide A (FPA) and inflammation-CD40 ligand, myeloperoxidase (MPO), tumor necrosis factor α (TNF-α), monocyte chemotactic protein-1 (MCP-1), and nitric oxide (NO), and compared to control group comprised of 100 healthy volunteers. Our study shows that ESRD patients exhibit activation of the coagulation and inflammatory processes.


Assuntos
Proteínas Sanguíneas/análise , Mediadores da Inflamação/sangue , Falência Renal Crônica/sangue , Trombose/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Coagulação Sanguínea , Feminino , Humanos , Inflamação/sangue , Inflamação/mortalidade , Falência Renal Crônica/mortalidade , Masculino , Pessoa de Meia-Idade , Trombose/mortalidade , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...